A Study to Assess the Safety, Tolerability, and Immunogenicity of 3 Lots of a Multivalent Pneumococcal Conjugate Vaccine Administered to Adults

November 6, 2026 updated by: Pfizer

A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF 3 LOTS OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN ADULTS

The purpose of this study is to provide safety data and demonstrate lot consistency with the PG4 vaccine by evaluating the immunogenicity of 3 different lots of this vaccine.

This study will compare a new pneumococcal vaccine with the vaccine currently in use to see if they are similarly safe. It will also compare three batches of the new vaccine to make sure they work the same way. Blood samples will be taken to measure how the body responds to the vaccines.

The study will be conducted in the United States. Participants will be assigned to 1 of 4 groups. Group 1: PG4 vaccine lot 1; Group 2: PG4 vaccine lot 2; Group 3: PG4 vaccine lot 3; Group 4: 20vPnC.

Within each group, participants will be assigned by chance in a 2:2:2:1 ratio to receive 1 vaccine injection (shot) with either PG4 (new vaccine) lot 1, PG4 lot 2, PG4 Lot 3 or 20vPnC, given in the arm. This means that for every 7 participants, about 2 will receive either PG4 lot 1, lot 2 or lot 3 and about 1 will receive 20vPnC.

Each participant will take part in the study for approximately 6 months.

Study Overview

Study Type

Interventional

Enrollment (Actual)

4701

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alabama
      • Birmingham, Alabama, United States, 35216
        • Achieve Clinical Research, LLC d/b/a Accel Research Sites - Birmingham Clinical Research Unit
    • California
      • Lake Forest, California, United States, 92630
        • Orange County Research Center
      • Walnut Creek, California, United States, 94598
        • Diablo Clinical Research, LLC dba Flourish Research
    • Connecticut
      • Milford, Connecticut, United States, 06460
        • Clinical Research Consulting
    • Florida
      • Doral, Florida, United States, 33172
        • Suncoast Research Associates
      • Hollywood, Florida, United States, 33024
        • Research Centers of America
      • Jacksonville, Florida, United States, 32216
        • East Coast Institute for Research, LLC
      • Miami, Florida, United States, 33176
        • Entrust Clinical Research
      • Miami Lakes, Florida, United States, 33014
        • Palm Springs Community Health Center
      • Miami Lakes, Florida, United States, 33016
        • Indago Research and Health Center, Inc.
      • Palmetto Bay, Florida, United States, 33157
        • Innovation Medical Research, LLC
      • West Palm Beach, Florida, United States, 33409
        • Palm Beach Research Center
    • Georgia
      • Fayetteville, Georgia, United States, 30214
        • Javara Inc.
      • Stockbridge, Georgia, United States, 30281
        • Clinical Research Atlanta
    • Hawaii
      • Honolulu, Hawaii, United States, 96814
        • East-West Medical Research Institute
    • Illinois
      • Melrose Park, Illinois, United States, 60160
        • DM Clinical Research
    • Iowa
      • Sioux City, Iowa, United States, 51106
        • Velocity Clinical Research, Sioux City
    • Michigan
      • Grosse Pointe Woods, Michigan, United States, 48236
        • Henry Ford St. John Hospital - Thomas Mackey Center for Infectious Disease Research
    • Missouri
      • Chesterfield, Missouri, United States, 63005
        • Clinical Research Professionals
      • Springfield, Missouri, United States, 65802
        • Bio-Kinetic Clinical Applications, LLC dba QPS-MO
      • Springfield, Missouri, United States, 65807
        • Bio-Kinetic Clinical Applications, LLC dba QPS-MO-Screening and Recruitment Center
      • St Louis, Missouri, United States, 63141
        • Sundance Clinical Research, LLC
    • Nebraska
      • Grand Island, Nebraska, United States, 68803
        • Velocity Clinical Research, Grand Island
    • New Jersey
      • Somers Point, New Jersey, United States, 08244
        • South Jersey Infectious Disease
    • North Carolina
      • Wilmington, North Carolina, United States, 28401
        • Accellacare - Wilmington
    • Ohio
      • Cincinnati, Ohio, United States, 45212
        • CTI Clinical Research Center
      • Cincinnati, Ohio, United States, 45206
        • Cincinnati Children's Hospital Medical Center Vaccine Research Center
      • Cincinnati, Ohio, United States, 45206
        • Cincinnati Children's Hospital Medical Center Investigational Drug Services
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19107
        • DM Clinical Research
    • South Carolina
      • Moncks Corner, South Carolina, United States, 29461
        • Clinical Trials of South Carolina
      • Myrtle Beach, South Carolina, United States, 29572
        • TMA Headlands LLC (d/b/a Trial Management Associates)
      • North Charleston, South Carolina, United States, 29405
        • Coastal Carolina Research Center, LLC
    • Texas
      • Mesquite, Texas, United States, 75149
        • SMS Clinical Research LLC
      • Sugar Land, Texas, United States, 77478
        • DM Clinical Research - Sugar Land
      • Tomball, Texas, United States, 77375
        • DM Clinical Research
    • Utah
      • Salt Lake City, Utah, United States, 84109
        • J. Lewis Research, Inc. / Foothill Family Clinic
      • Salt Lake City, Utah, United States, 84121
        • J. Lewis Research, Inc. / Foothill Family Clinic South

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 49 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

Adults 18 through 49 years of age, who have no history of receiving a pneumococcal vaccine after 5 years of age.

Exclusion Criteria:

Individuals with a history of severe allergic reactions to a vaccine or its components, serious chronic medical disorders, significant psychiatric conditions, known or suspected immunodeficiency, substance abuse issues, asplenia, bleeding diathesis or prolonged bleeding, a history of a prior confirmed invasive pneumococcal infection, and pregnant or breastfeeding females will be excluded from enrollment in the trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PG4 Vaccine Lot 3

Multivalent Pneumococcal Vaccine

Multivalent Pneumococcal Vaccine

Other Names:
  • PG4 lot 1
  • PG4 Lot 2
  • PG4 Lot 3
Experimental: PG4 Vaccine Lot 2

Multivalent Pneumococcal Vaccine

Multivalent Pneumococcal Vaccine

Other Names:
  • PG4 lot 1
  • PG4 Lot 2
  • PG4 Lot 3
Experimental: PG4 Vaccine Lot 1

Multivalent Pneumococcal Vaccine

Multivalent Pneumococcal Vaccine

Other Names:
  • PG4 lot 1
  • PG4 Lot 2
  • PG4 Lot 3
Active Comparator: 20 Valent Pneumococcal Conjugate Vaccine (20vPnC)

20 Valent Pneumococcal Conjugate Vaccine

20 Valent Pneumococcal Conjugate Vaccine

Other Names:
  • Prevnar 20

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Percentage of Participants with Prespecified Local Reactions Within 7 Days After Vaccination
Time Frame: Within 7 days after Vaccination

Prompted local reactions after each dose

Within 7 days after Vaccination
Percentage of Participants reporting Prespecified Systemic Events Within 7 Days after Vaccination
Time Frame: Within 7 days after Vaccination

Prompted systemic events after each dose

Within 7 days after Vaccination
Percentage of Participants with Adverse Events (AEs)
Time Frame: From Vaccination to 1 month after Vaccination

AEs occurring from Dose 1 to 1 month after the vaccination

From Vaccination to 1 month after Vaccination
Percentage of Participants with Serious Adverse Events (SAEs)
Time Frame: From Vaccination to 6 months after Vaccination

SAEs occurring from Dose 1 to 6 months after the vaccination

From Vaccination to 6 months after Vaccination
OPA geometric mean ratios (GMR) between each pair of PG4 vaccine lots
Time Frame: 1 month after Vaccination

OPA GMRs between each pair of PG4 vaccine lots at 1 month after vaccination

1 month after Vaccination

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
OPA Serotype-specific geometric mean titers (GMT) for PG4 vaccine serotypes
Time Frame: 1 month after Vaccination

OPA GMTs at 1 month after vaccination

1 month after Vaccination
OPA geometric mean fold rise (GMFR) for PG4 vaccine serotypes
Time Frame: From before vaccination to 1 month after vaccination

GMFRs in OPA titers from before to 1 month after vaccination

From before vaccination to 1 month after vaccination
Percentages of participants with a ≥4-fold rise in opsonophagocytic activity (OPA) titers
Time Frame: From Vaccination to 6 months after Vaccination

Percentages of participants with a ≥4-fold rise in OPA titers from before to 1 month after vaccination

From Vaccination to 6 months after Vaccination
Percentages of participants with OPA titers ≥ lower limit of quantitation (LLOQ)
Time Frame: From before vaccination to 1 month after vaccination

Percentages of participants with OPA titers ≥ lower limit of quantitation (LLOQ) from before vaccination to 1 month after vaccination

From before vaccination to 1 month after vaccination

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Director: Pfizer CT.gov Call Center, Pfizer

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 8, 2026

Primary Completion (Estimated)

April 26, 2027

Study Completion (Estimated)

April 26, 2027

Study Registration Dates

First Submitted

August 26, 2026

First Submitted That Met QC Criteria

August 26, 2026

First Posted (Actual)

August 31, 2026

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

November 6, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

IPD Plan Description

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe